glp-1 receptor agonist nephrolithiasis agonists in patients with chronic kidney disease and either overweight or obesity GLP-1 receptor agonists and next-generation
Description
10 This means that semaglutide (GLP-1 RA) drugs are not silver bullets for sustained weight loss
I., Spyrou, N., Mantzoros, C
To increase the plasma half-life by avoiding renal elimination, GLP-1 analogs were modified by adding acyl groups (liraglutide and semaglutide) or large molecules such as albumin (albiglutide) and the Fc portion of IgG (dulaglutide)
Common Side Effects
Future incretin-based therapies Future research in incretin-based treatment of overweight and obesity aims to investigate the potential of combining GLP-1-R agonism with the targeting of other peptide hormones to achieve synergistic effects, with the most prominent targets of interest being the GIPR, the glucagon receptor (GCGR) and the amylin receptor [16]
